Bruce N. Jacobs - Mar 1, 2023 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Financial Officer
Signature
/s/ Bruce N. Jacobs
Stock symbol
KYMR
Transactions as of
Mar 1, 2023
Transactions value $
-$42,465
Form type
4
Date filed
3/3/2023, 03:30 PM
Previous filing
Oct 24, 2022
Next filing
Jun 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Award $0 +23.8K +28.9% $0.00 106K Mar 1, 2023 Direct F1, F2
transaction KYMR Common Stock Sale -$32.6K -1.06K -1% $30.88 105K Mar 2, 2023 Direct F3, F4
transaction KYMR Common Stock Sale -$9.86K -314 -0.3% $31.40 105K Mar 2, 2023 Direct F3, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Award $0 +143K $0.00 143K Mar 1, 2023 Common Stock 143K $32.07 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.
F2 This number includes 909 shares acquired under the Registrant's employee stock purchase plan on December 1, 2022.
F3 Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 to $31.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.32 to $31.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.